No Data
No Data
Teva Pharmaceuticals Presents 4th Interim Analysis Of PEARL Migraine Prevention Study At EAN Congress; New Sub-Analysis Highlights Potential Negative Impact Of Treatment Pauses On Patient Outcomes
4th interim analysis of PEARL real world migraine prevention study presented at 10th European Association of Neurology (EAN) congress in HelsinkiNew sub-analysis of PEARL data highlights potential neg
Teva Pharmaceutical Indus Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 06/27/2024 39.56% Jefferies $19 → $23 Maintains Buy 06/05/2024 27.43% Barclays $20 → $21 Maintains Overwei
Amdocs Goes Ex Dividend Tomorrow
Gain Rotation Out of Semis Is Feeding Into Other Parts of the Market - Argus
Top 3 Tech Stocks Which Could Rescue Your Portfolio In June
The most oversold stocks in the information technology sector presents an opportunity to buy into undervalued companies.The RSI is a momentum indicator, which compares a stock's strength on days when
Teva Pharmaceutical Industries Launches Authorized Generic Of Victoza In United States
Generic Victoza is the first-ever generic GLP-1 and supports increased demand for this category of therapies in the U.S. market.This launch adds to Teva's continued commitment to its complex generic m